יצרן | |
---|---|
ארץ ייצור |
Japan |
Retinomax Screeen
- Upwards-tilting LCD- The low-reflection, 3.5inch monitor, featuring a tilting head with 100 degree, stepless range of motion means ease of use in keeping with the current generation of user-friendly devices.
- Improved battery life- At 180 minutes, the battery capacity is now twice that of conventional models
- Automatic Axis Compensation and extended measurement range
- Focus Assist- Lets you know the exact focusing point with the following color-coding system.
- New Child Mode- While the measurement is being taken, a melody plays continually to keep children’s attention. A constantly changing color display, both on the outside and inside of the device, also keeps children involved during the process
מתעניין במוצר? שלח לנו פרטים ונציג יחזור אליך
Category: Anterior Diagnostics
Additional information
Reviews (0)
Be the first to review “Retinomax Screeen” Cancel reply
Related products
®RIBOFAST
RIBOFAST is a patented dextran free ophthalmic solution, fit for every CXL protocol. Thanks to Vitamin E TPGS as an enhancer, it allows for an effective penetration in the whole corneal stroma, including in EPI-ON, for safe and effective results.
FEATURES:
- Dextran free ophthalmic solution;
- International patent;
- Vitamin E TPGS: corneal penetration enhancer;
- High effectiveness in both EPI-ON and EPI-OFF;
- Can be used with every protocol and UV device on the market;
- Can be used in CUSTOM FAST CXL (cfCXL).
2WIN
Kaleidos
RIBOCROSS te
RIBOCROSS ® te is a patented ophthalmic solution, fit for every CXL protocol. Thanks to Vitamin E TPGS as an enhancer, it allows for an effective penetration in the whole corneal stroma, including in EPI-ON, for safe and effective results.
FEATURES:
- Ophthalmic solution with 10% Dextran;
- International patent;
- Vitamin E TPGS: corneal penetration enhancer;
- High effectiveness in both EPI-ON and EPI-OFF;
- Can be used with every protocol and UV device on the market;
- Can be used in CUSTOM FAST CXL (cfCXL)
Reviews
There are no reviews yet.